OTC Markets OTCPK - Delayed Quote USD

Leisure Acquisition Corp. (ENSCW)

0.0150

+0.0020

+(15.38%)

At close: April 23 at 2:18:22 PM EDT

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Ensysce Biosciences, Inc (NASDAQ:ENSC) stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as per data from Benzinga Pro. Ensysce Biosciences on Wednesday received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof including both composition of matter and method of use claims. PF9001, the medication covered by this patent, is designed to pr

Benzinga 16 hours ago

ENSCW
+15.38%
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse ...

ACCESS Newswire 16 hours ago

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~ ~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a ...

ACCESS Newswire yesterday

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~ SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical ...

ACCESS Newswire 9 days ago

ENSC
+96.26%
ENSCW
+15.38%
ENSC Shows Compound Protects Against Abuse

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that have plagued the American public. In pursuit of that goal, the company released data from a study on its PF614-MPAR compound that is

Zacks Small Cap Research 9 days ago

ENSCW
+15.38%
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for ...

ACCESS Newswire 24 days ago

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the ...

ACCESS Newswire last month

ENSC
+96.26%
ENSCW
+15.38%
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

New York, NY, March 13, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The update note includes information on Ensysce Biosciences’ business model, services, industry, financial results, valuation, and risks. The update note is available below. Ensysce March 2025 Update Note Highlights from the note include: Ensysce Biosciences Advances

GlobeNewswire last month

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations

Ensysce Biosciences ( NASDAQ:ENSC ) Full Year 2024 Results Key Financial Results Revenue: US$5.21m (up 134% from FY...

Simply Wall St. last month

ENSC
+96.26%
ENSCW
+15.38%
ENSC Starts 2025 in Great Shape

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) released its 4Q2024 results that showed a good cash balance of $3.5 million due in large part to the financing activities management has undertaken which we’ve described in earlier reports, as well as a focus on controlling administrative expenses. In 2024, the company announced that it has

Zacks Small Cap Research last month

ENSCW
+15.38%
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ...

ACCESS Newswire last month

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for ...

ACCESS Newswire last month

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ: ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS, Program Director with Creighton University. The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are less prone to accidental overdose and abuse.

PR Newswire last month

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

SAN DIEGO, CA / ACCESS Newswire / February 5, 2025 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for ...

ACCESS Newswire 2 months ago

ENSC
+96.26%
ENSCW
+15.38%
When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)?

With the business potentially at an important milestone, we thought we'd take a closer look at Ensysce Biosciences...

Simply Wall St. 2 months ago

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim ...

ACCESS Newswire 2 months ago

ENSC
+96.26%
ENSCW
+15.38%
ENSC Continues to Announce Potential Life-Changing Results

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit abuse and overdoses. Opioid abuse is a national crisis, with the CDC estimating over 75,000 deaths from opioid overdoses and there are

Zacks Small Cap Research 2 months ago

ENSCW
+15.38%
Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today issued a letter to shareholders ...

ACCESS Newswire 3 months ago

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that on December ...

ACCESS Newswire 3 months ago

ENSC
+96.26%
ENSCW
+15.38%
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the receipt ...

ACCESS Newswire 4 months ago

ENSC
+96.26%
ENSCW
+15.38%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Leisure Acquisition Corp. (ENSCW)

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

ENSC Shows Compound Protects Against Abuse

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations

ENSC Starts 2025 in Great Shape

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

When Can We Expect A Profit From Ensysce Biosciences, Inc. (NASDAQ:ENSC)?

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

ENSC Continues to Announce Potential Life-Changing Results

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product